Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 8 years
- Director since
- 2023
8 years of board service in total across 4 boards, counting each seat separately. Longest: Rhythm Pharmaceuticals Inc., 3 years.
Rhythm Pharmaceuticals Inc.
Director · President and CEO
Trevi Therapeutics Inc.
Director
Pharvaris N.V.
Director
Kardigan Inc.
Director
Chief executive roles
Rhythm Pharmaceuticals Inc.
· President and CEO
Dates unknown
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Rhythm Pharmaceuticals Inc. June 24, 202696.9%
-
Trevi Therapeutics Inc. June 13, 202471.6%
-
Rhythm Pharmaceuticals Inc. June 21, 202396.5%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 14, 2026 | Rhythm Pharmaceuticals Inc. | Option exercise | +50,000 | $6.05 | $302,500 |
| Sep 14, 2026 | Rhythm Pharmaceuticals Inc. | Open-market sale | −6,439 | $101.75 | $655,145 |
| Sep 14, 2026 | Rhythm Pharmaceuticals Inc. | Open-market sale | −30,746 | $102.35 | $3,146,761 |
| Sep 14, 2026 | Rhythm Pharmaceuticals Inc. | Open-market sale | −8,698 | $103.43 | $899,634 |
| Sep 14, 2026 | Rhythm Pharmaceuticals Inc. | Open-market sale | −1,817 | $104.55 | $189,965 |
| Sep 14, 2026 | Rhythm Pharmaceuticals Inc. | Open-market sale | −2,300 | $105.19 | $241,937 |
| Jun 17, 2026 | Kardigan Inc. | Grant or award | +20,706 | — | — |
| Feb 1, 2026 | Rhythm Pharmaceuticals Inc. | Option exercise | +68,713 | — | — |
| Feb 1, 2026 | Rhythm Pharmaceuticals Inc. | Shares withheld for tax | −31,522 | $108.99 | $3,435,583 |
| Jun 3, 2025 | Rhythm Pharmaceuticals Inc. | Option exercise | +43,620 | $4.59 | $200,216 |
| Jun 3, 2025 | Rhythm Pharmaceuticals Inc. | Open-market sale | −43,346 | $65.04 | $2,819,224 |
| Jun 3, 2025 | Rhythm Pharmaceuticals Inc. | Open-market sale | −274 | $65.60 | $17,974 |
| Feb 19, 2025 | Rhythm Pharmaceuticals Inc. | Open-market sale | −9,896 | $57.22 | $566,249 |
| Feb 16, 2025 | Rhythm Pharmaceuticals Inc. | Option exercise | +21,250 | — | — |
| Feb 4, 2025 | Rhythm Pharmaceuticals Inc. | Open-market sale | −4,278 | $59.43 | $254,242 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.